Listen

Add to my selection

ENTYVIO

Medicine - Posted on Nov 23 2022

Active substance (DCI)

védolizumab

history (5)

10/19/22

ENTYVIO (védolizumab) - Pochite chronique active modérée à sévère

Key points Considering all of this information and after discussions and a vote, the Committee deems that for the indication...

CAV :
54321

icône flèche
9/16/20

ENTYVIO

Key points Favourable opinion for reimbursement in the following indications: treatment of adult patients with moderately to...

CAV :
54321

icône flèche
3/18/20

ENTYVIO (védolizumab)

Key points Favourable opinion for reimbursement in the treatment of ulcerative colitis (UC) in TNFα antagonist-naive adult p...

CAV :
54321

icône flèche
12/6/17

ENTYVIO (vedolizumab), anti-α4β7 integrin

In the treatment of Crohn’s disease: Noclinical added value but Substantial clinical benefit in patients who have failed a c...

icône flèche
1/7/15

ENTYVIO (vedolizumab), anti-α4β7 integrin

In patients who failed corticosteroids, immunomodulators and TNFα antagonist therapy: minor improvement in the treatment of ...

CAV :
54321

icône flèche

Technical information

ATC code

L04AA33

Manufacturer

TAKEDA FRANCE

Presentation

ENTYVIO 108 mg, solution injectable en seringue préremplie
1 seringue préremple (CIP : 34009 302 086 4 9)
2 seringues préremples (CIP : 34009 302 086 6 3)
6 seringues préremples (CIP : 34009 550 740 2 1)

ENTYVIO 108 mg, solution injectable en stylo prérempli
1 stylo prérempli (CIP : 34009 302 086 7 0)
2 stylos préremplis (CIP : 34009 302 086 8 7)
6 stylos préremplis (CIP : 34009 550 740 3 8)

ENTYVIO 300 mg, poudre pour solution à diluer pour perfusion (code CIS : 66320218)
1 flacon(s) en verre de 20 mL (CIP : 34009 586 728 7 3)

All our publications

Esophageal and gastrointestinal diseases

Health economics